MTOR and neoplasm: Combinational treatment of mTOR (AZD8055) with either MEK (trametinib) or BRD4 (JQ1) inhibitors to EIF1AX-A113splice knock-in tumour cell lines result in reduced c-MYC and mTOR protein levels and consequent tumour size reduction [82].